Claims for Patent: 10,717,958

Summary for Patent: 10,717,958

Title:	Method for producing a product (e.g. polypeptide) in a continuous cell culture fermentation process
Abstract:	A method for improving productivity in microbial fermentations and mammalian cell culture bioreactors.
Inventor(s):	Laustsen; Mads (Gentofte, DK)
Assignee:	CMC BIOLOGICS A/S (Soborg, DK)
Application Number:	16/400,201
Patent Claims:	1. A method for producing a product selected from a biopolymer expressed by a cell or microorganism, an intracellular or extracellular product produced by a cell or microorganism, a periplasmatic product produced by a cell or microorganism, in a first and a second bioreactor in a chemostat fermentation process, wherein said first bioreactor comprises: i) optionally a first outlet having a separation device allowing impurities with a size below the size of the product, and medium to be removed while retaining the product in the bioreactor; (ii) a second outlet having a product harvest module allowing the product, impurities and medium to be removed; and (iii) an inlet for adding a medium; wherein said second bioreactor comprises: (iv) a third outlet having a separation device allowing impurities with a size below the size of the product, and medium to be removed while retaining the product in the bioreactor; (v) a fourth outlet having a product harvest module allowing the product, impurities and medium to be removed; and (vi) an inlet for adding a medium; (vii) an inlet for adding cells or microorganisms and a medium from the first bioreactor; wherein the first bioreactor is for growth of cells or microorganisms and the second bioreactor is for induction of production of the biopolymer, the intracellular or extracellular product, or the periplasmatic product, and wherein the first and second bioreactor operates in series, wherein the method comprises the following steps: (a) growing and optionally fermenting the cells or microorganisms expressing the biopolymer, the cells or microorganisms roducing the intracellular or extracellular product, the cells or microorganisms producing the periplasmatic product, the cells or the microorganisms in the first bioreactor in a suitable medium under suitable conditions, wherein during the growing and optionally fermentation impurities and medium are removed via the separation device, the product, impurities and medium are removed via the product harvest module and new medium is added to replenish nutrients consumed by the cells or microorganisms and to equilibrate the medium removed during removal of impurities and harvesting the product (b) transporting the product, impurities and medium removed via the product harvest module to the second bioreactor, containing cells or microorganisms grown in the first bioreactor, induction of production of the biopolymer, the intracellular or extracellular product, or the periplasmatic product, wherein during the production impurities and medium are removed via the separation device, the product, impurities and medium are removed via the product harvest module and new medium is added to replenish nutrients consumed by the cells or microorganisms and to equilibrate the medium removed during removal of impurities and harvesting the product; and (c) the product is isolated from the harvested medium; and wherein the cell density of the cells or microorganisms in the bioreactor during the fermentation reaches at least 5 million cells per ml medium. 2. The method of claim 1, wherein the product is selected from a bio polymer. 3. The method of claim 2, wherein the biopolymer is expressed by at least one cell or microorganism selected from the group consisting of E. coli, Bacillus, yeast from the genus of Saccharomyces, Pichia, Aspergillus, Fusarium, Kluyveromyces, CHO (Chinese Hamster Ovary) cell, hybridomas, BHK (Baby Hamster Kidney) cell, myeloma cell, HEK-293 cell, human lymphoblastoid cell, a human cell and a mouse cell. 4. The method of claim 2, wherein the biopolymer is a polypeptide or protein. 5. The method of claim 4, wherein the polypeptide is an antibody or fragment thereof, Human growth hormone, Follicle-stimulating hormone, Factor VIII, Factor VII, Factor IX Erythropoietin (EPO), Granulocyte colony-stimulating factor (G-CSF), alpha-glactosidase A, alpha-L-iduronidase (rhIDU; laronidase), N-acetylgalactosamine-4-sulfatase (rhASB; galsulfase), DNAse, Tissue plasminogen activator (TPA), Glucocerebrosidase, Interferon (IF), Insulin, Insulin derivative, Insulin-like growth factor 1, Tenecteplase, antihemophilic factor, human coagulation factor, Etanercept, Trastuzumab, Infliximab, Basiliximab, Belimumab, Daclizumab, Adalimumab Abciximabor, Afutuzumab, Alemtuzumab, Cetuximab, Daclizumab, Denosumab, Eculizumab, Edrecolomab, Golimumab, Ibritumomab tiuxetan, Mepolizumab, Motavizumab, Natalizumab, Ofatumumab, Omalizumab, Oregovomab, Palivizumab, Pemtumomab, Pertuzumab, Ranibizumab, Rituximab, Tefibazumab and Zanolimumab. 6. The method of claim 1, wherein the product is selected from an intracellular product or from a periplasmatic product from a microorganism or from a cell. 7. The method of claim 1, wherein the product is selected from an extracellular product from a microorganism or from a cell. 8. The method of claim 1, wherein the microorganism is yeast or bacteria. 9. The method of claim 1, wherein the cell is a mammalian cell. 10. The method of claim 1, wherein the cell density in the bioreactors during the fermentation reaches at least 10 million cells per ml medium. 11. The method of claim 1, wherein each bioreactor has a volume of at least 50 L. 12. The method of claim 1, wherein impurities are removed via the separation device of the second bioreactor by one flow rate through the separation device and the product is harvested through the product harvest module by a second flow rate through the product harvest module, wherein the first flow rate refers to the flow rate of medium and impurities through the separation device and the second flow rate refers to the flow rate of product, cells, impurities and medium through the product harvest module, wherein the ratio between the first flow rate and the second flow rate is from 1:1 to 9:1. 13. The method of claim 12, wherein the separation device of the second bioreactor is selected from an impurity filter unit or a gravitational separation unit or a centrifugal separation unit. 14. The method of claim 13, wherein the impurity unit is a membrane filter. 15. The method of claim 14, wherein the membrane filter has a nominal molecular weight cutoff (NMWC) pore sizes of at least 1000 NMWC. 16. The method of claim 15, wherein the membrane filter has a nominal molecular weight cut-off (NMWC) pore sizes within the range of 2,000 to 15,000 NMWC. 17. The method of claim 14, wherein the membrane filter has a nominal molecular weight cut-off (NMWC) pore size of a maximum of 80% of the MW of the product. 18. The method of claim 1, wherein the first bioreactor comprises the first outlet having a separation device allowing impurities with a size below the size of the product, and medium to be removed while retaining the product in the bioreactor. 19. The method of claim 18, wherein the separation device of the first bioreactor is selected from an impurity filter unit or a gravitational separation unit or a centrifugal separation unit. 20. The method of claim 1, wherein the isolated product is formulated into a pharmaceutical composition.

Details for Patent 10,717,958

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Grifols Therapeutics Llc	KOATE, KOATE-DVI	antihemophilic factor (human)	For Injection	101130	01/24/1974		2033-03-19
Baxalta Us Inc.	HEMOFIL M	antihemophilic factor (human)	For Injection	101448	03/14/2001		2033-03-19
Genentech, Inc.	RITUXAN	rituximab	Injection	103705	11/26/1997		2033-03-19
Hoffmann-la Roche Inc.	ZENAPAX	daclizumab	Injection	103749	12/10/1997		2033-03-19